U-Pump
Overview: U-Pump is a MedTech startup revolutionizing diabetes care with the world’s first AI-powered, reusable insulin patch pump. Our solution targets the 80% of insulin-dependent patients who are currently priced out or underserved by traditional insulin pumps. With a focus on affordability, precision, and accessibility, U-Pump is on a mission to make smart insulin therapy available to millions worldwide. Product & Technology: U-Pump combines Swiss-level precision engineering, seamless CGM (Dexcom, Libre) integration, and a modular, eco-friendly cartridge system. Our proprietary OneMove™ technology enables painless, one-step application, while AI-powered dosing ensures real-time glucose control and reduction of hypoglycemia risk. The reusable patch design cuts insulin therapy costs by up to 60% and reduces medical waste. Traction: - Functional MVP completed and metrological validation passed - 435 pre-orders, including 131 paid orders totaling $14,000 - 2 patents filed, 4 more in progress - LTV/CAC ratio: 5.6 | Gross margins: 80–90% - Projected Year 1 revenue: $127M, Year 4: $1.4B - Preparing FDA 510(k) pre-submission - Early engagement with Dexcom Ventures and DCB (Diabetes Center Berne) Business Model: U-Pump operates on a hybrid model combining hardware sales, AI-driven software, and a subscription-based refill system with insurance integration. Our direct-to-consumer and B2B2C approach ensures scalable entry across regulated markets. Target Markets: U.S., EU, Israel, and MENA regions with expansion planned across global high-incidence diabetes zones. Global insulin pump market projected to reach $13B+ by 2029. Funding: Currently raising $5M via SAFE (starting from $200K) to complete regulatory milestones, launch in key markets, and accelerate growth. Headquarters: Delaware, United States R&D and Strategy: Israel & EU
U-Pump
Overview: U-Pump is a MedTech startup revolutionizing diabetes care with the world’s first AI-powered, reusable insulin patch pump. Our solution targets the 80% of insulin-dependent patients who are currently priced out or underserved by traditional insulin pumps. With a focus on affordability, precision, and accessibility, U-Pump is on a mission to make smart insulin therapy available to millions worldwide. Product & Technology: U-Pump combines Swiss-level precision engineering, seamless CGM (Dexcom, Libre) integration, and a modular, eco-friendly cartridge system. Our proprietary OneMove™ technology enables painless, one-step application, while AI-powered dosing ensures real-time glucose control and reduction of hypoglycemia risk. The reusable patch design cuts insulin therapy costs by up to 60% and reduces medical waste. Traction: - Functional MVP completed and metrological validation passed - 435 pre-orders, including 131 paid orders totaling $14,000 - 2 patents filed, 4 more in progress - LTV/CAC ratio: 5.6 | Gross margins: 80–90% - Projected Year 1 revenue: $127M, Year 4: $1.4B - Preparing FDA 510(k) pre-submission - Early engagement with Dexcom Ventures and DCB (Diabetes Center Berne) Business Model: U-Pump operates on a hybrid model combining hardware sales, AI-driven software, and a subscription-based refill system with insurance integration. Our direct-to-consumer and B2B2C approach ensures scalable entry across regulated markets. Target Markets: U.S., EU, Israel, and MENA regions with expansion planned across global high-incidence diabetes zones. Global insulin pump market projected to reach $13B+ by 2029. Funding: Currently raising $5M via SAFE (starting from $200K) to complete regulatory milestones, launch in key markets, and accelerate growth. Headquarters: Delaware, United States R&D and Strategy: Israel & EU